GBI Research has released its pharma research, “”Ophthalmology Therapeutics in Major Developed Markets to 2019 New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies””, which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.

Scope

• Disease overview and treatment usage patterns
• Market size and forecast for glaucoma and DES in Top Eight Markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) from 2012 to 2019
• Major marketed products for the indications types covered
• In-depth pipeline analysis for glaucoma and DES
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements in the ophthalmology market

Reasons to buy

• The report will enhance your decision-making capability by allowing you to
• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

1 Table of Contents 6

1.1 List of Tables 8

1.2 List of Figures 9

2 Ophthalmology Therapeutics in Major Markets - Introduction 10

2.1 Dry Eye Syndrome 10

2.1.1 Classification 10

2.1.2 Symptoms 10

2.1.3 Etiology 10

2.1.4 Pathophysiology 11

2.1.5 Diagnosis 12

2.1.6 Epidemiology 13

2.1.7 Prognosis 14

2.1.8 Treatment Options 14

2.2 Glaucoma 15

2.2.1 Classification 15

2.2.2 Symptoms 16

2.2.3 Etiology 16

2.2.4 Pathophysiology 17

2.2.5 Diagnosis 17

2.2.6 Epidemiology 18

2.2.7 Prognosis 19

2.2.8 Treatment Options 19

3 Ophthalmology Therapeutics in Major Markets - Marketed Products (Global) 21

3.1 Dry Eye Syndrome 21

3.2 Glaucoma 21

3.3 Key Marketed Products 22

3.3.1 Restasis 22

3.3.2 Systane 23

3.3.3 Diquas 24

3.3.4 Mucosta 25

3.3.5 Hyalein 26

3.3.6 Lumigan 27

3.3.7 Alphagan/Alphagan P 28

3.3.8 Simbrinza 29

4 Ophthalmology Therapeutics in Major Markets - Pipeline Analysis 30

4.1 Dry Eye Syndrome Pipeline 30

4.1.1 Overall Pipeline 30

4.1.2 Pipeline Analysis by Molecule Type 32

4.1.3 Pipeline Analysis by Mechanism of Action 34

4.2 Glaucoma Pipeline 36

4.2.1 Overall Pipeline 36

4.2.2 Pipeline Analysis by Molecule Type 38

4.2.3 Pipeline Analysis by Mechanism of Action 39

4.3 Promising Drug Candidates in the Pipeline 41

4.3.1 CF-101 41

4.3.2 MIM-D3 41

4.3.3 SAR-1118 41

4.3.4 DE-111 42

5 Ophthalmology Therapeutics in Major Markets - Market Forecast to 2019 43

5.1 Major Markets 43

5.1.1 Treatment Usage Patterns 43

5.1.2 Annual Cost of Therapy 43

5.1.3 Market Size 43

5.2 The US 45

5.2.1 Treatment Usage Patterns 45

5.2.2 Annual Cost of Therapy 45

5.2.3 Market Size 45

5.3 Top Five European Countries 47

5.3.1 Treatment Usage Patterns 47

5.3.2 Annual Cost of Therapy 47

5.3.3 Market Size 47

5.4 Canada 49

5.4.1 Treatment Usage Patterns 49

5.4.2 Annual Cost of Therapy 49

5.4.3 Market Size 49

5.5 Japan 51

5.5.1 Treatment Usage Patterns 51

5.5.2 Annual Cost of Therapy 51

5.5.3 Market Size 51

5.6 Drivers and Barriers 53

5.6.1 Drivers 53

5.6.2 Barriers 53

6 Ophthalmology Therapeutics in Major Markets - Deals and Strategic Consolidations (Global) 55

6.1 Deals Analysis 55

6.2 Major Co-Development Deals 57

6.2.1 NicOx Signs Research Agreement with Pfizer 58

6.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 58

6.2.3 Akorn Enters into Agreement with Azad Pharma 58

6.3 Major Licensing Deals 59

6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 60

6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 60

6.3.3 Asterand Enters into Licensing Agreement with Allergan 60

7 Ophthalmology Therapeutics in Major Markets - Appendix 61

7.1 All Pipeline Drugs by Phase 61

7.1.1 Discovery 61

7.1.2 Preclinical 61

7.1.3 IND/CTA-filed 63

7.1.4 Phase I 63

7.1.5 Phase II 64

7.1.6 Phase III 65

7.1.7 Pre-registration 65

7.1.8 Undisclosed 66

7.2 Market Forecasts to 2019 66

7.2.1 Major Markets 66

7.2.2 The US 67

7.2.3 The UK 67

7.2.4 France 68

7.2.5 Germany 69

7.2.6 Italy 69

7.2.7 Spain 70

7.2.8 Canada 71

7.2.9 Japan 71

7.3 Market Definitions 72

7.4 Abbreviations 72

7.5 Sources 74

7.6 Research Methodology 75

7.6.1 Coverage 76

7.6.2 Secondary Research 76

7.6.3 Primary Research 76

7.6.4 Therapeutic Landscape 77

7.6.5 Geographical Landscape 80

7.6.6 Pipeline Analysis 80

7.7 Expert Panel Validation 80

7.8 Contact Us 80

7.9 Disclaimer 80

List of Tables

Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 14

Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 15

Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 19

Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 61

Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 61

Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 63

Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 63

Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 64

Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 65

Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 65

Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 66

Table 12: Ophthalmology Therapeutics Market, Major Markets,, Dry Eye Syndrome, Market Forecast, 2012-2019 66

Table 13: Ophthalmology Therapeutics Market, Major Markets, Glaucoma, Market Forecast, 2012-2019 66

Table 14: Ophthalmology Therapeutics Market, The US, Dry Eye Syndrome, Market Forecast, 2012-2019 67

Table 15: Ophthalmology Therapeutics Market, The US, Glaucoma, Market Forecast, 2012-2019 67

Table 16: Ophthalmology Therapeutics Market, The UK, Dry Eye Syndrome, Market Forecast, 2012-2019 67

Table 17: Ophthalmology Therapeutics Market, The UK, Glaucoma, Market Forecast, 2012-2019 68

Table 18: Ophthalmology Therapeutics Market, France, Dry Eye Syndrome, Market Forecast, 2012-2019 68

Table 19: Ophthalmology Therapeutics Market, France, Glaucoma, Market Forecast, 2012-2019 68

Table 20: Ophthalmology Therapeutics Market, Germany, Dry Eye Syndrome, Market Forecast, 2012-2019 69

Table 21: Ophthalmology Therapeutics Market, Germany, Glaucoma, Market Forecast, 2012-2019 69

Table 22: Ophthalmology Therapeutics Market, Italy, Dry Eye Syndrome, Market Forecast, 2012-2019 69

Table 23: Ophthalmology Therapeutics Market, Italy, Glaucoma, Market Forecast, 2012-2019 70

Table 24: Ophthalmology Therapeutics Market, Spain, Dry Eye Syndrome, Market Forecast, 2012-2019 70

Table 25: Ophthalmology Therapeutics Market, Spain, Glaucoma, Market Forecast, 2012-2019 70

Table 26: Ophthalmology Therapeutics Market, Canada, Dry Eye Syndrome, Market Forecast, 2012-2019 71

Table 27: Ophthalmology Therapeutics Market, Canada, Glaucoma, Market Forecast, 2012-2019 71

Table 28: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012-2019 71

Table 29: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012-2019 72

List of Figures

Figure 1: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006-2012 22

Figure 2: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010-2012 24

Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009-2012 25

Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009-2012 26

Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006-2012 27

Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006-2012 28

Figure 7: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 31

Figure 8: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 33

Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 35

Figure 10: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 37

Figure 11: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 38

Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 40

Figure 13: Ophthalmology Therapeutics Market, Major Markets, Market Size, 2012-2019 44

Figure 14: Ophthalmology Therapeutics Market, The US, Market Size, 2012-2019 46

Figure 15: Ophthalmology Therapeutics Market, Top Five European Countries, Market Size, 2012-2019 48

Figure 16: Ophthalmology Therapeutics Market, Canada, Market Size ($m), 2012-2019 50

Figure 17: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012-2019 52

Figure 18: Ophthalmology Therapeutics Market, Global, Deals, 2006-2013 56

Figure 19: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006-2013 57

Figure 20: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006-2013 59

Figure 21: GBI Research Market Forecasting Model 79